

# Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma

Information for the public

Published: 3 September 2018

Last updated: 1 May 2024

[www.nice.org.uk](http://www.nice.org.uk)

Pembrolizumab is not normally available for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had:

- a stem cell transplant using their own cells (autologous stem cell transplant) and
- brentuximab vedotin.

Your doctor should talk with you about other treatment options. If you are already taking pembrolizumab, you should be able to continue until you and your doctor decide when best to stop.

In **May 2024** we published [NICE technology appraisal guidance 967](#). It recommends pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over who have had brentuximab vedotin but cannot have an autologous stem cell transplant.

## Information and support

The [NHS webpage on Hodgkin lymphoma](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Lymphoma Association](#), 0808 808 5555
- [Leukaemia CARE](#), 08088 010 444
- [Macmillan Cancer Support](#), 0808 808 0000
- [Cancer Research UK](#), 0808 800 4040

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6009-5